The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance-Reference-Cited by-同舟云学术

The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance

Published:2006-11 Issue:10 Volume:17 Page:1171-1177
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

de Anta Josep M.,Pérez-Castro Antonio J.,Freire Raimundo,Mayol Xavier

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference30 articles.

1. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage;Kinsella;Br J Cancer,1997

2. Apoptosis: a link between cancer genetics and chemotherapy;Johnstone;Cell,2002

3. The pharmacology nd clinical use of methotrexate;Jolivet;N Engl J Med,1983

4. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase;Banerjee;Biochim Biophys Acta,2002

5. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells;Lesuffleur;Cancer Res,1990

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels;Journal of Oncology;2023-02-25

2. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL;Molecular Cancer Therapeutics;2017-05-31

3. Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene;PLOS ONE;2016-09-29

4. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance;Experimental Cell Research;2012-06

5. Wnt5a as a Predictor in Poor Clinical Outcome of Patients and a Mediator in Chemoresistance of Ovarian Cancer;International Journal of Gynecologic Cancer;2011-01